Dr Mark Socinski Discusses the Cost-effectiveness of Biomarker Testing in NSCLC

Mark A. Socinski, MD, executive director at AdventHealth Cancer Institute, shares insight on the cost-effectiveness and utility of biomarker testing in non–small cell lung cancer (NSCLC).

Related Keywords

Marka Socinski , ,Adventhealth Cancer Institute ,Cost Effectiveness ,Nsclc ,Adventhealth ,Biomarker Testing ,Genomic Testing ,